VA
TERN

VR Adviser’s Terns Pharmaceuticals TERN Stock Holding History

VR Adviser’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,077,090
Closed -$5.97M – 40
2024
Q4 		$5.97M Sell
1,077,090
-2,332,968
-68% -$15.8M 0.41% 28
2024
Q3 		$28.4M Hold
3,410,058
– – 1.49% 19
2024
Q2 		$23.2M Hold
3,410,058
– – 1.48% 21
2024
Q1 		$22.4M Sell
3,410,058
-1,087,059
-24% -$7.1M 1.06% 25
2023
Q4 		$29.2M Buy
4,497,117
+1,404,844
+45% +$7.43M 2% 14
2023
Q3 		$15.6M Buy
3,092,273
+119,404
+4% +$758K 1.64% 20
2023
Q2 		$26M Sell
2,972,869
-646,653
-18% -$7.54M 4.16% 9
2023
Q1 		$42.9M Sell
3,619,522
-88,369
-2% -$844K 8.37% 4
2022
Q4 		$37.7M Hold
3,707,891
– – 6.36% 5
2022
Q3 		$21.8M Buy
+3,707,891
New +$13.8M 3.37% 9

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

VR Adviser's TERN Position: Q1 2025 in Review

VR Adviser sold out of Terns Pharmaceuticals (TERN) in Q1 2025, closing a stake of 1,077,090 shares — an estimated $5.97M sold.

VR Adviser first reported a position in TERN in Q3 2022 and held it in 10 quarters. The position peaked at $42.9M in Q1 2023. 137 funds tracked by Wall St. Rank hold TERN as of Q1 2025.

  • VR Adviser reported no remaining Terns Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • VR Adviser sold 1,077,090 Terns Pharmaceuticals shares in Q1 2025, an estimated $5.97M.
  • VR Adviser first reported a position in Terns Pharmaceuticals in Q3 2022 and held it in 10 quarters.
  • VR Adviser's Terns Pharmaceuticals position peaked at $42.9M in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2025.

Based on VR Adviser's 13F filing for Q1 2025, filed 15 May 2025.